Markers of increased atherosclerotic risk in patients with chronic kidney disease: A preliminary study

Lipids in Health and Disease

Volumn 15, Issue 1, 2016, Pages

  Gluba Brzózka, Anna ^a   Michalska Kasiczak, Marta ^a   Franczyk, Beata ^a   Nocuń, Marek ^b   Toth, Peter ^c,d   Banach, MacIej ^a   Rysz, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^c CGH Medical Center   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 CARBOXYGLUTAMIC ACID; FETUIN A; GELATINASE A; GELATINASE B; OSTEOCALCIN; OSTEOPONTIN; OSTEOPROTEGERIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; BIOLOGICAL MARKER; CALCIUM BINDING PROTEIN; MATRIX GLA PROTEIN; SCLEROPROTEIN; TIMP1 PROTEIN, HUMAN; TIMP2 PROTEIN, HUMAN;

AGED; AORTA VALVE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; FEMALE; HEART ARRHYTHMIA; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE; PREVALENCE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SYSTOLIC DYSFUNCTION; TRICUSPID VALVE DISEASE; BLOOD; CHRONIC KIDNEY FAILURE; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; ALPHA-2-HS-GLYCOPROTEIN; BIOMARKERS; CALCIUM-BINDING PROTEINS; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OSTEOCALCIN; OSTEOPONTIN; OSTEOPROTEGERIN; RENAL INSUFFICIENCY, CHRONIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84957942415     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-016-0191-x     Document Type: Article

References (99)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1-150.
2. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis. 2002;39 suppl 1:S1-266.
3. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ. 2010;341:c4986.
4. Franczyk-Skóra B, Gluba-Brzózka A, Wranicz JK, Banach M, Olszewski R, Rysz J. Sudden cardiac death in CKD patients. Int Urol Nephrol. 2015;47(6):971-82.
5. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154-69.
6. Brosius III FC, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation. 2006;114:1083-7.
7. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32:853-906.
8. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112-9.
9. London GM, Marchais SJ, Guerin AP, et al. Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant. 2002;17:1713-24.
10. Franczyk-Skóra B, Gluba A, Olszewski R, Banach M, Rysz J. Heart function disturbances in chronic kidney disease - echocardiographic indices. Arch Med Sci. 2014;10(6):1109-16.
11. R Development Core Team. R: a language and environment for statistical computing. Wieden, Austria: R Foundation for Statistical Computing; 2011.
12. Martínez-Castelao A, Górriz JL, Portolés JM, De Alvaro F, Cases A, Luño J, et al. Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study. BMC Nephrol. 2011;12:53.
13. Incidence, prevalence, patient characteristics, & modality. http://www.usrds.org/2012/pdf/v2-ch1-12.pdf
14. Levin A, Thompson CR, Ethier J, Carlisle EJF, Tobe S, Mendelssohn D, et al. Left ventricular mass index in early renal disease. Impact of a decline in hemoglobin. Am J Kidney Dis. 1999;34:125-34.
15. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186-92.
16. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The long-term evolution of uremic cardiomyopathy. Kidney Int. 1998;54:1720-5.
17. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. JASN. 2001;12(5):1079-84.
18. Arodiwe EB, Ulasi II, Ijoma CK, Ike SO. Left ventricular diastolic function in a predialysis patient population. West Afr J Med. 2010;29(4):225-9.
19. Han JH, Han JS, Kim EJ, Doh FM, Koo HM, Kim CH, et al. Diastolic dysfunction is an independent predictor of cardiovascular events in incident dialysis patients with preserved systolic function. PLoS One. 2015;10(3), e0118694.
20. de Bie MK, Ajmone Marsan N, Gaasbeek A, Bax JJ, Groeneveld M, Gabreels BA, et al. Left ventricular diastolic dysfunction in dialysis patients assessed by novel speckle tracking strain rate analysis: prevalence and determinants. Int J Nephrol. 2012;2012:963504.
21. Wang AYM, Wang M, Lam CWK, Chan IHS, Zhang Y, Sanderson JE. Left ventricular filling pressure by Doppler echocardiography in patients with end-stage renal disease. Hypertension. 2008;52(1):107-14.
22. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18:1731-40.
23. Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996;16:978-83.
24. Westenfeld R, Schäfer C, Krüger T, Haarmann C, Schurgers LJ, Reutelingsperger C, et al. Fetuin-A protects against atherosclerotic calcification in CKD. J Am Soc Nephrol. 2009;20(6):1264-74.
25. Janicka L, Czekajska-Chebab E, Duma D, et al. The study of several risk factors of calcification in coronary vessels in patients treated with peritoneal dialysis. Pol Arch Med Wewn. 2006;4:14-20. In Polish.
26. Relterowa M, Moe SM. Vascular calcification in dialysis patients: Pathogenesis and consequences. Am J Kidney Dis. 2003;41(3 Suppl 1):S96-9.
27. Leskinen Y, Paana T, Saha H, Groundstroem K, Lehtimäki T, Kilpinen S, et al. Valvular calcification and its relationship to atherosclerosis in chronic kidney disease. J Heart Valve Dis. 2009;18(4):429-38.
28. Brenner BM. Remission of renal disease: recounting the challenge, acquiring the goal. J Clin Invest. 2002;110:1753-8.
29. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol. 2009;20:1453-64.
30. Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: A prospective study. J Am Soc Nephrol. 2003;14:159-68.
31. Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int. 2003;63:1003-11.
32. Wada T, McKee MD, Steitz S, et al. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res. 1999;84:166-78.
33. Price PA, Parthemore JG, Deftos LJ. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. J Clin Invest. 1980;66:878-83.
34. Delmas PD, Wilson DM, Mann KG, et al. Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab. 1983;57:1028-30.
35. Hermans MM, Vermeer C, Kooman JP, Brandenburg V, Ketteler M, Gladziwa U, et al. Undercarboxylated matrix GLA protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index. Blood Purif. 2007;25:395-401.
36. Shroff RC, Shah V, Hiorns MP, Schoppet M, Hofbauer LC, Hawa G, et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant. 2008;23:3263-71.
37. Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: The calcification inhibitor in need of vitamin K. Thromb Haemost. 2008;100:593-603.
38. Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol. 2010;5(4):568-75.
39. Jono S, McKee MD, Murry CE, Shioi A, Morii HO, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87(7):E10-7.
40. Jiang JQ, Lin S, Xu PC, Zheng ZF, Jia JY. Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder. Nephrology (Carlton). 2011;16(6):588-94.
41. Morena M, Jaussent I, Dupuy AM, Bargnoux AS, Kuster N, Chenine L, et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant. 2015 [Epub ahead of print]
42. Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, et al. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension. 2007;49:1392-8.
43. Nascimento MM, Hayashi SY, Riella MC, Lindholm B. Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease. Braz J Med Biol Res. 2014 [Epub ahead of print]
44. Anand DV, Lim E, Darko D, Bassett P, Hopkins D, Lipkin D, et al. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol. 2007;50:2218-25.
45. Beaussier H, Masson I, Collin C, Bozec E, Laloux B, Calvet D, et al. Carotid plaque, arterial stiffness gradient, and remodeling in hypertension. Hypertension. 2008;52:729-36.
46. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet. 2003;361:827-33.
47. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, et al. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int. 2007;72:202-7.
48. Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004;35:1636-41.
49. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest. 1994;94:1597-604.
50. Barreto DV, Lenglet A, Liabeuf S, Kretschmer A, Barreto FC, Nollet A, et al. Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease. Nephron Clin Pract. 2011;117(4):c363-72.
51. Kadoglou NP, Gerasimidis T, Golemati S, Kapelouzou A, Karayannacos PE, Liapis CD. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J Vasc Surg. 2008;47:55-62.
52. Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H, et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis. 2003;170:333-7.
53. Singh M, Foster CR, Dalal S, Singh K. Osteopontin: role in extracellular matrix deposition and myocardial remodeling post-MI. J Mol Cell Cardiol. 2010;48:538-43.
54. Sand JM, Larsen L, Hogaboam C, Martinez F, Han M, Røssel Larsen M, et al. MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis - validation of two novel biomarker assays. PloS one. 2013;8(12):e84934.
55. Pasterkamp G, Schoneveld AH, Hijnen DJ, de Kleijn DPV, Teepen H, van der Wal AC, et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis. 2000;150:245-53.
56. Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, et al. Molecules. 2013;18(12):15314-28.
57. Sweet MJ, Leung BP, Kang D, Sogaard M, Schulz K, Trajkovic V, et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol. 2001;166:6633-9.
58. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J. 2001;141:211-7.
59. Higo S, Uematsu M, Yamagishi M, Ishibashi-Ueda H, Awata M, Morozumi T, et al. Elevation of plasma matrix metalloproteinase-9 in the culprit coronary artery in patients with acute myocardial infarction: Clinical evidence from distal protection. Circ J. 2005;69:1180-5.
60. Guzel S, Serin O, Guzel EC, Buyuk B, Yllmaz G, Güvenen G. Interleukin-33, Matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in myocardial infarction. Korean J Intern Med. 2013;28:165-73.
61. Chang H-R, Yang S-F, Li M-L, Lin C-C, Hsieh Y-S, Lian J-D. Relationship between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease. Clin Chim Acta. 2006;366:243-8.
62. Pawlak K, Pawlak D, Mysliwiec M. Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients. Atherosclerosis. 2007;190:199-204.
63. Chen NX, O'Neill KD, Chen X, Kiattisunthorn K, Gattone VH, Moe SM. Activation of Arterial Matrix Metalloproteinases Leads to Vascular Calcification in Chronic Kidney Disease. Am J Nephrol. 2011;34:211-9.
64. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008;19:213-6.
65. Musial K, Zwolinska D. Pleiotropic functions of TIMP-1 in patients with chronic kidney disease. Cell Mol Life Sci. 2014;71(8):1547-8.
66. Musial K, Zwolinska D. Novel indicators of fibrosis-related complications in children with chronic kidney disease. Clin Chim Acta. 2014;430:15-9.
67. Wang L, Wang J, Wang Y, Fu Q, Lei YH, Nie ZY, et al. Protective effect of exogenous matrix metalloproteinase-9 on chronic renal failure. Exp Ther Med. 2014;7(2):329-34.
68. Duymelinck C, Dauwe SE, De Greef KE, et al. TIMP-1 gene expression and PAI-1 antigen after unilateral ureteral obstruction in the adult male rat. Kidney Int. 2000;58:1186-201.
69. Hörstrup JH, Gehrmann M, Schneider B, et al. Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease. Nephrol Dial Transplant. 2002;17:1005-13.
70. Musial K, Zwolinska D. Matrix metalloproteinases (MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment. Cell Stress Chaperones. 2011;16(1):97-103.
71. Rysz J, Banach M, Stolarek RA, Mikhailidis DP, Cialkowska-Rysz A, Pokoca L, et al. Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. Int Urol Nephrol. 2011;43(2):491-8.
72. Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens. 2004;17(9):764-9.
73. Death AK, Nakhla S, McGrath KC, Martell S, Yue DK, Jessup W, et al. Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages. J Am Coll Cardiol. 2002;39(12):1943-50.
74. Eickelberg O, Roth M, Mussmann R, et al. Calcium channel blockers activate the interleukin-6 gene via the transcription factors NF-IL-6 and NF-KB in primary human vascular smooth muscle cells. Circulation. 1999;99:2276-82.
75. Funck RC, Wilke A, Rupp H, Brilla CG. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol. 1997;432:35-44.
76. Papakonstantinou E, Roth M, Kokkas B, Papadopoulos C, Karakiulakis G. Losartan inhibits the angiotensin II-induced modifications on fibrinloysis and matrix deposition by primary human vascular smooth muscle cells. J Cardiovasc Pharmacol. 2001;38:715-28.
77. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13:422-30.
78. Schrier RW. Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol. 2007;3:637.
79. Ahmed A, Campbell RC. Epidemiology of Chronic Kidney Disease in Heart Failure. Heart Fail Clin. 2008;4(4):387-99.
80. López B, González A, Lindner D, Westermann D, Ravassa S, Beaumont J, et al. Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? Cardiovasc Res. 2013;99(1):111-20.
81. Rosenberg M, Zugck C, Nelles M, Juenger C, Frank D, Remppis A, et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail. 2008;1(1):43-9.
82. Papazafiropoulou A, Tentolouris N. Matrix metalloproteinases and cardiovascular diseases. Hippokratia. 2009;13(2):76-82.
83. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDLC) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER (HDL)). Clin Biochem. 2001;34:583-8.
84. Yildiz G, Duman A, Aydin H, Yilmaz A, Hür E, Maʇden K, et al. Evaluation of association between atherogenic index of plasma and intima-media thickness of the carotid artery for subclinic atherosclerosis in patients on maintenance hemodialysis. Hemodial Int. 2013;17(3):397-405.
85. Siomou E, Challa A, Printza N, Giapros V, Petropoulou F, Mitsioni A, et al. Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. Pediatr Nephrol. 2011;26(7):1105-14.
86. Tedla FM, Brar A, Browne R, Brown C. Hypertension in Chronic Kidney Disease: Navigating the Evidence. Int J Hypert. 2011;2011:132405.
87. Appel G. Lipid abnormalities in renal disease. Kidney Int. 1991;39:169.
88. Sentí M, Romero R, Pedro-Botet J, et al. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int. 1992;41:1394.
89. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993;21:573.
90. Tsimihodimos V, Mitrogianni Z, Elisaf M. Dyslipidemia Associated with Chronic Kidney Disease. Open Cardiovasc Med J. 2011;5:41-8.
91. Weiner DE, Sarnak MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med. 2004;19:1045.
92. Vaziri ND, Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif. 2011;31(1-3):189-96.
93. Kalantar-Zadeh K, Kuwae N, Regidor DL. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kid Int. 2006;70:771-80.
94. Narisawa S, Harmey D, Yadav MC. Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res. 2007;22:1700-10.
95. Westenfeld R, Schäfer C, Smeets R, Brandenburg VM, Floege J, Ketteler M, et al. Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant. 2007;22(6):1537-46.
96. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004;95:560-7.
97. Chen NX, O'Neill KD, Duan D, Moe SM. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int. 2002;62:1724-31.
98. Odenbach J, Wang X, Cooper S, Chow FL, Oka T, Lopaschuk G, et al. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension. 2011;57(1):123-30.
99. Pawlak K, Tankiewicz J, Mysliwiec M, Pawlak D. Systemic levels of MMP2/TIMP2 and cardiovascular risk in CAPD patients. Nephron Clin Pract. 2010;115:c251-8.